The Irish-based company, founded in 2009, is focused on advancing acute stroke treatment by capturing and removing clots from blood vessels to restore blood flow. Its EmboTrap®II Revascularization Device is CE marked and commercially available in Europe, while being available for investigational use only in the United States. Neuravi collaborates with international researchers and clinicians through the Neuravi Thromboembolic Initiative (NTI) to deepen the understanding of clot and occlusion dynamics, with the goal of improving patient outcomes in stroke. In April 2017, Neuravi was acquired by Codman Neuro and is now part of the Johnson and Johnson family of medical device companies.